Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein.
Hashimoto. Y Y; Ito. Y Y; Niikura. T T; Shao. Z Z; Hata. M M; Oyama. F F; Nishimoto. I I
Key Findings
- Humanin gene or peptide stops neuron death caused by the Swedish mutant APP linked to familial Alzheimer’s disease
- Humanin protects cells from amyloid‑beta toxicity even though it doesn’t reduce amyloid secretion
- The protective action involves two targets: the intracellular toxic pathway triggered by mutant APP and the extracellular amyloid‑beta toxicity
Practical Outcomes
- Humanin appears to have neuroprotective effects in cell models of Alzheimer’s, suggesting it could be a candidate for longevity or brain‑health supplements. However, the research is limited to laboratory cells, so there are no dosage guidelines or proven benefits for humans yet. Biohackers should view this as early‑stage evidence and await clinical studies before incorporating humanin into protocols.
Summary
The study shows that the small protein humanin can protect brain cells from dying when they are exposed to a mutant form of the amyloid precursor protein linked to Alzheimer’s disease. It works by blocking the toxic effects inside the cell and also by defending against the harmful amyloid‑beta peptide, without actually lowering the amount of amyloid produced.
Abstract
We report a novel gene, designated Humanin (HN) cDNA, that suppresses neuronal cell death by K595N/M596L-APP (NL-APP), a mutant causing familial Alzheimer's disease (FAD), termed Swedish mutant. Transfection of neuronal cells with HN cDNA or treatment with the coding HN polypeptide abrogated cytotoxicity by NL-APP. HN suppressed neurotoxicity by Abeta1-43 in the absence of N2 supplement, but could not inhibit Abeta secretion from NL-APP. HN could also protect neuronal cells from death by NL-APP lacking the 41st and 42nd residues of the Abeta region. Therefore, HN suppressed neuronal cell death by NL-APP not through inhibition of Abeta42 secretion, but with two targets for its inhibitory action: (i) the intracellular toxic mechanism directly triggered by NL-APP and (ii) neurotoxicity by Abeta. HN will contribute to the development of curative therapy of AD, especially as a novel reagent that could mechanistically supplement Abeta-production inhibitors.
Study Information
pubmed
2001
2001-05-04T00:00:00.000Z
10.1006/bbrc.2001.4765